advertisement
Purpose. To evaluate the efficacy and safety profile of a new crosslinked sodium hyaluronate drainage implant in nonpenetrating glaucoma surgery. Methods. From July 2008 until January 2010, 55 eyes from 55 patients with glaucoma were operated upon. After a standard deep sclerectomy was performed, a crosslinked sodium hyaluronate (HEALAflow((registered trademark))) was injected under the superficial scleral flap and underneath the conjunctiva. The main outcomes measured were mean intraocular pressure (IOP), mean number of antiglaucoma medications, presence of postoperative complications, and clinical aspect of the filtering bleb. results. For the 55 eyes, the mean follow-up was 12.0(plus or minus)5.1 months, the mean preoperative IOP was 21.6(plus or minus)7.2 mmHg, and the mean number of antiglaucoma medications before surgery was 2.4(plus or minus)1.2. At final follow-up visits, the mean IOP went down to 11.5(plus or minus)3.0 mmHg; the mean number of antiglaucoma medications was reduced to 0.5(plus or minus)0.9. The filtering bleb was visible on 49 eyes (89%). There were 5 hypotonies (IOP < 6 mmHg) and 3 iris incarcerations. Complete success rate (IOP (less-than or equal to)18 mmHg without antiglaucoma medication) was 70% and the overall success rate (IOP (less-than or equal to)18 mmHg with and without antiglaucoma medication) was 91%. ConClusions. The slow resorbable highly crosslinked sodium hyaluronate drainage implant fills up the intrascleral and subconjunctival space, preventing postoperative scarring and fibrosis of the filtering site and helping to maintain a functional filtration after nonpenetrating glaucoma surgery. The IOP was significantly lowered with few numbers of postoperative complications and less medication.
S. Roy. Glaucoma Center, Montchoisi Clinic Lausanne, Lausanne, Switzerland. Email: sylvain.roy@epfl.ch
12.8.2 With tube implant or other drainage devices (Part of: 12 Surgical treatment > 12.8 Filtering surgery)